1. Intensive aphasia therapy improves low mood in fluent post-stroke aphasia: Evidence from a case-controlled study
- Author
-
Lisa Edelkraut, Sergio E. Starkstein, Cristina Green-Heredia, Friedemann Pulvermüller, Marcelo L. Berthier, Bettina Mohr, and Guadalupe Dávila
- Subjects
030506 rehabilitation ,medicine.medical_specialty ,Speech Therapy ,behavioral disciplines and activities ,Lateralization of brain function ,03 medical and health sciences ,0302 clinical medicine ,Arts and Humanities (miscellaneous) ,Aphasia ,medicine ,Post-stroke depression ,Humans ,Applied Psychology ,Depression (differential diagnoses) ,business.industry ,Rehabilitation ,Case-control study ,Stroke Rehabilitation ,Neuropsychology and Physiological Psychology ,Mood ,Case-Control Studies ,Post stroke ,Physical therapy ,Language Therapy ,Active treatment ,medicine.symptom ,0305 other medical science ,business ,030217 neurology & neurosurgery - Abstract
Introduction: Depressive symptoms are a major drawback of aphasia, negatively impacting on functional outcomes. In a previous study, Intensive Language-Action Therapy (ILAT) was effective in improving depression and low mood in persons with chronic non-fluent aphasia. We present a proof-of-concept case-control study that evaluates language and mood outcomes amongst persons with fluent post-stroke aphasia.Participants: Thirteen Spanish speaking persons with fluent aphasia due to chronic stroke lesions in the left hemisphere participated in the study.Intervention: Five participants (intervention group) received ILAT for 3 h/day during two consecutive weeks, for an overall of 30 h, and 8 participants (control group) entered a waiting-list no-treatment arm.Results: The main finding was that participants receiving active treatment showed significant improvements on depression and aphasia severity scores, whereas no significant changes were found in the control group.Conclusions: The implementation of ILAT was efficient in improving clinical language deficits in people with fluent aphasia and contributes to improvement in mood after therapy.Trial registration: EUDRACT (2008-008481-12).
- Published
- 2020